Autopsy report · NCT02532400

Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients

“Hard to enroll expected number of eligible patients.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months before it started.
• Ran for about 3 years before it stopped.
• 21 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Ruijin Hospital

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

Neoadjuvant endocrine therapy; Neoadjuvant chemotherapy

Participants

21

Sites

1

Countries

China

Trials that died the same way

• Ethanol Locks for the Treatment of Central Venous Line Infections
  “inability to enroll adequate number of patients” (81% match in meaning)
• Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)
  “difficulty of enrolling patients” (80% match in meaning)
• Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer
  “Difficulty in enrolling patients” (78% match in meaning)
• Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease
  “due to the difficulty to enroll suitable patients” (77% match in meaning)
• Quadrant Versus Superficial Parotidectomy
  “Lack of enrollment of eligible patients for randomization.” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.